{"nctId":"NCT02006706","briefTitle":"A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy","startDateStruct":{"date":"2006-08-10","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":15,"armGroups":[{"label":"MabThera/Rituxan","type":"EXPERIMENTAL","interventionNames":["Drug: rituximab [MabThera/Rituxan]","Drug: methotrexate","Drug: methylprednisolone"]}],"interventions":[{"name":"rituximab [MabThera/Rituxan]","otherNames":[]},{"name":"methotrexate","otherNames":[]},{"name":"methylprednisolone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, 18-80 years of age;\n* rheumatoid arthritis after inadequate response to \\>=1 DMARD treatment;\n* active disease;\n* DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study treatment.\n\nExclusion Criteria:\n\n* autoimmune disease other than rheumatoid arthritis;\n* bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within 24 weeks of MabThera infusion;\n* concurrent treatment with any DMARD or antiTNF-alfa;\n* intra-articular or parenteral corticosteroids within 4 weeks prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24","description":"DAS28 was calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PGA) of disease activity (participant-rated arthritis activity assessment using visual analog scale \\[VAS\\]) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (â‰¤)3.2 equals (=) low disease activity, DAS28 greater than (\\>)3.2 to 5.1 = moderate to high disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"Health Assessment Questionnaire-Disability Index (HAQ-DI)","description":"HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"0.687"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.960"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":14},"commonTop":[]}}}